title: Dexlansoprazole MR: a review.
abstract: Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a novel system, the dual delayed release formulation. The drug has been shown to be efficacious in healing erosive esophagitis as compared with lansoprazole. When compared to placebo, dexlansoprazole provided significantly higher maintenance rates for healed esophageal mucosa in patients with erosive esophagitis and symptom control in patients with non-erosive reflux disease. Dexlansoprazole could be taken without regard to food. Overall, dexlansoprazole is well tolerated and has a comparable side-effect profile to lansoprazole.
authors.affiliation: Neuroenteric Clinical Research Group, Southern Arizona VA Health Care System, Tucson, USA.
authors.forename: Tiberiu
authors.initials: T
authors.lastname: Hershcovici
authors.forename: Lokesh K
authors.initials: LK
authors.lastname: Jha
authors.forename: Ronnie
authors.initials: R
authors.lastname: Fass
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D064748:Dexlansoprazole; D004941:Esophagitis / Q000188:drug therapy* / Q000503:physiopathology; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D064747:Lansoprazole; D009092:Mucous Membrane / Q000473:pathology; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013237:Stereoisomerism
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D003692:Delayed-Action Preparations; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064748:Dexlansoprazole